EMA Authorised: Stayveer (bosentan (as monohydrate)) — Janssen-Cilag International NV

View source ↗

Summary

The EMA authorised Stayveer (bosentan) for use in pulmonary arterial hypertension and systemic sclerosis (scleroderma) in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Systemic Sclerosis

Drugs mentioned

• Stayveer (bosentan)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary;Scleroderma, Systemic. MAH: Janssen-Cilag International NV. Decision date: 22/10/2024